Didanosine: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Didanosine''' (2′,3′-dideoxyinosine | '''Didanosine''' (2′,3′-dideoxyinosine,'''DDI''') is sold under the trade names '''Videx''' and '''Videx EC'''. It is a [[reverse transcriptase inhibitor]], effective against [[HIV]] and used in combination with other [[antiretroviral drug]] therapy as part of highly active antiretroviral therapy (HAART). | ||
==Category== | ==Category== | ||
Revision as of 22:17, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Didanosine (2′,3′-dideoxyinosine,DDI) is sold under the trade names Videx and Videx EC. It is a reverse transcriptase inhibitor, effective against HIV and used in combination with other antiretroviral drug therapy as part of highly active antiretroviral therapy (HAART).
Category
Antiretroviral
US Brand Names
Videx®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages